These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
23. Re: early relapses after the first dose of natalizumab in active multiple sclerosis. Haartsen J; Marriott M; Butzkueven H Mult Scler; 2009 Apr; 15(4):520. PubMed ID: 19324983 [No Abstract] [Full Text] [Related]
24. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Brousil JA; Roberts RJ; Schlein AL Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095 [TBL] [Abstract][Full Text] [Related]
30. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. Weissert R Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774 [No Abstract] [Full Text] [Related]
31. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722 [TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil. Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719 [TBL] [Abstract][Full Text] [Related]
35. Natalizumab for multiple sclerosis? Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381 [TBL] [Abstract][Full Text] [Related]